63 results about "Microbial biomarkers" patented technology

The invention provides a microbial marker of colorectal cancer and application of the marker. The microbial marker comprises Faecalibacterium, Streptococcus and Fusobacterium. The microbial marker ofcolorectal cancer has high precision of predicting the risk of colorectal cancer and high sensitivity, only the abundance of the microbial marker of colorectal cancer needs to be obtained, a risk early warning is given out through model calculation, and the possibility of getting colorectal cancer is evaluated. The microbial marker can be used for preventing colorectal cancer, warning a subject and giving the subject a prompt about whether it is necessary to further conduct diagnosis confirmation or not, and is also conductive for individuals to improve the intestinal microbial environment byadjusting diet or medical treatment, so that the risk of getting colorectal cancer is reduced for the individuals.

The invention discloses a mental disorder related intestinal tract microbial marker and application thereof. The intestinal tract microbial marker refers to one or more combinations of intestinal tract microbial florae of Prevotella and Bacteroides. The invention further discloses application of the mental disorder related intestinal tract microbial marker in preparing reagents for diagnosing mental disorders and methods for screening food, probiotics or drugs capable of intervening with mental disorders. Particularly, the methods include comparing proportion of microbial florae of Prevotella to microbial florae of Bacteroides before and after treatment or interference of the food, probiotics or drugs and / or comparing relative quantity of microbial florae of Prevotella and microbial florae of Bacteroides in feces specimens.

The invention belongs to the field of biomedicine and relates to application of a tuberculosis microbial marker in the preparation of reagents for predicting or assisting in diagnosing tuberculosis state of a subject. The invention also discloses a method of using a tuberculosis marker to determine the state of an individual. The tuberculosis microbial marker claimed herein provides significant differences between tuberculous patients and healthy ones, may act as a marker to distinguish healthy people and tuberculous patients, and may predict, diagnose or prognose tuberculosis.

The present invention relates to the identification of pancreatic cancer biomarkers for the detection of early pancreatic cancer. The present invention also provides methods of diagnosing pancreatic cancer and distinguishing between pancreatic cancer and chronic pancreatitis. The present invention additionally provides kits that find use in the practice of the methods of the invention.

Disclosed are methods for identifying and / or classifying microbes using one or more single nucleotide polymorphisms (SNPs) in 16S ribosomal RNA (16S rRNA) of prokaryotes and / or one or more SNPs in 5.8S ribosomal RNA (5.8S rRNA) of eukaryotes. Also disclosed are probes, primers and kits that are useful in those methods. Methods for the diagnosis of sepsis based upon these SNPs are also disclosed.

The invention provides a colorectal cancer microbial marker and application thereof. The colorectal cancer microbial marker comprises microorganism, wherein the microorganism comprises any one or a combination of at least two of Treptococcus bovis, Clostridium septicum, Parvimonas micra and Helicobacter pylori. The colorectal cancer microbial marker provided by the invention has the potential of being used as a colorectal cancer marker, the content of the colorectal cancer microbial marker in an excrement sample of a patient suffering from colorectal cancer is remarkably higher than the content of the colorectal cancer microbial marker in an excrement sample of a healthy individual, statistical significance is obtained, whether an individual suffers from the colorectal cancer or not can berelatively accurately determined, and a colorectal cancer non-invasively auxiliary diagnosis function is obtained.

The invention discloses a microbial marker of liver cirrhosis, and an application. The microbial marker is one or more selected from one microorganism of Veillonella atypica ACS-134-V-Col7a enriched in a patient group suffering the liver cirrhosis or two microorganisms of Bacteroides uniformis ATCC8492 and Clostridiales enriched in a healthy group. The invention also relates to a drug for treating the liver cirrhosis. A drug for treating the liver cirrhosis can promote or increase one or two selected from the two microorganisms of Bacteroides uniformis ATCC8492 and Clostridiales enriched in the healthy group, and / or suppress or clear the microorganism of Veillonella atypica ACS-134-V-Col7a enriched in the patient group suffering the liver cirrhosis. The method detects relative abundance of the microbial marker in intestinal flora and compares the obtained relative abundance value and a predetermined cutoff value. The invention also relates to a beneficial microorganism combination or functional food. The beneficial microorganism combination or functional food comprises one or two of the two microorganisms of Bacteroides uniformis ATCC8492 and Clostridiales enriched in the healthy group. The invention also relates to a kit for detecting the liver cirrhosis, monitoring a treatment process, or producing and screening the drug. The kit is used for detecting the microbial marker.

The present invention relates to the field of medicine and in particular to celiac disease (CD). Specifically the present invention relates to methods and means for detection of CD using novel microbiomarker, celiac gut index (CGI). The invention relates also to methods and means for treatment or prophylaxis of CD. The present invention provides a novel product comprising a gut microbiome altering agent that, when administered to an individual, improves the state of health of individuals suffering or susceptible to suffer from celiac disease and possibly reduces the likelihood of acquiring celiac disease. The product of the invention provides a natural and safe manner for the treatment of celiac disease. The present invention provides also a novel method for aiding diagnosis of CD by the specific gut health biomarker, Celiac Gut Index (GCI). In the method a probability of a subject having celiac disease is determined by measuring the relative abundances of one or more microbial taxa in a fecal sample from a subject; and the probability of the subject having CD is determined based on the measured abundances as celiac gut index (CGI).

The invention provides a microbial marker of type II diabetes mellitus and an application of the microbial marker. The microbial marker comprises a composition of Eggerthella, Erysipelotrichaceae, Faecalitalea, Lachnospiraceae_ge and Lachnoclostridium. The microbial marker of the type II diabetes millitus has a high correlation with the type II diabetes millitus, can be used to assist in the diagnosis or early warning of the risk of the type II diabetes mellitus, and is also beneficial for individuals to improve the microenvironment of intestinal bacterial by adjusting diet or medical interference, thereby reducing the risk of developing the type II diabetes mellitus.

The invention provides a microbial marker for assessing the risk of type II diabetes and application of the microbial marker. The microbial marker comprises a combination of any two or more of bifidobacterium, prevotella, clostridium, roseburia, enterococcus and veillonella. The microbial marker has high sensitivity in predication of the risk of the type II diabetes; a risk warning is given through model calculation only after the relative content of the microbial marker is acquired; the microbial marker can be used for auxiliary diagnosis to guide adjustment of the intestinal microbial environment, and accordingly, the risk of suffering from diabetes is reduced.

The invention provides microbial markers for predicting the risk of colorectal cancer and application of the microbial marker. The microbial markers comprise the following three types: fusobacterium nucleatum, parvimonas micra and solobacter moorei. The abundance of the above three bacteria in a colorectal cancer patient is remarkably increased; corresponding microbial marker expression abundance values are obtained through an experimental method and input into a machine learning model established by the invention; and a risk value is given after the model conducts comprehensive calculation, so colorectal cancer is diagnosed in an assisted manner. The microbial markers provided by the invention are high in sensitivity and good in specificity, have the potential of serving as colorectal cancer markers, and provide a means for non-invasive auxiliary diagnosis of colorectal cancer.

The invention discloses an ankylosing spondylitis microbial marker, which is formed by the following microbes: Actinomyces sp. ICM47, Bifidobacterium breve, Bifidobacterium sp.12_1_47 BFAA, Bifidobacterium longum, Collinsella aerofaciens, Bifidobacterium bifidum and Bifidobacterium pseudocatenulatum. The invention also discloses a method and a device for determining an individual condition by utilizing the ankylosing spondylitis microbial marker. Compared with a healthy group, the ankylosing spondylitis microbial marker is obviously enriched in an ankylosing spondylitis patient population, and can be used as a distinction marker of the healthy population and the ankylosing spondylitis patient population.

The invention brings forward biomarkers for end-stage renal disease and an application thereof. The biomarkers for end-stage renal disease are Akkermansia muciniphila, Alistipes finegoldii, Alistipesshahii, Bacteroides fibrobacter, Bacteroides fragilis, Bifidobacterium dentium, Clostridium difficile, Clostridium saccharolyticum, Desulfovibrio Vulgaris, Eggerthella lenta, Enterococcus faecalis, Enterococcus faecium, Flavonifractor plautii, Fusobacterium nucleatum, butyric acid-producing enterobacteriaceae, Lactobacillus amylovorus, Lactobacillus casei, Lactobacillus fermentum, Lactobacillus plantarum, Streptococcus infantarius, Streptococcus thermophilus, butyrate-producing bacteria, Eubacterium rectal and Faecalibacterium prausnitzi. Whether a subject suffers from or is susceptible to end-stage renal disease can be effectively determined by determining these microbial markers in the intestinal flora of the subject.

The disclosure provides methods for rapid fractionation of circulating RNAs based on the type of carriers they locate in. The disclosure further provides that the methods of the disclosure can be used for diagnosing a disorder in a subject by identifying specific microRNA biomarkers associated with that disorder.

The invention discloses intestinal microorganism markers for detecting multiple myeloma diseases, and an application and detection preparation of the intestinal microorganism markers. The intestinal microorganism markers comprise citrobacter freundii, enterobacter cloacae, raoultella ornithinolytica, klebsiella aerogenes, klebsiella variicola, klebsiella pneumoniae, streptococcus salivarius, streptococcus oralis, streptococcus gordonii, streptococcus mitis, streptococcus pneumoniae, butyrate producing bacteria, clostridium butyricum and clostridium saccharobutylicum. The intestinal microbial markers can be used alone or in combination. The invention discloses a support vector machine (SVM) classification model constructed by taking the microbial markers as characteristics, and the SVM classification model is applied to clinical diagnosis of multiple myeloma diseases. The invention also discloses an application of the microorganism markers in preparation of a diagnostic preparation formultiple myeloma diseases.

The invention discloses application of microbial flora in acute pancreatitis. The microbial flora is Ruminococcus_gauvreauii_group. The microbial marker has high sensitivity and high specificity during prediction of acute pancreatitis. Through detection of the abundance of the microbial marker, subjects can be warned, and risks can be reduced further through dietary adjustment or medical intervention.

The invention belongs to the technical field of microorganisms, and particularly relates to a diarrhea-type irritable bowel syndrome intestinal microbial marker and application thereof. The enteric microbe marker comprises a Staphyloccus genus, an Akkermansia genus, an Enterobacter genus, a Dubosiella genus and a Lactobacillus genus. The level change of intestinal flora in mice with diarrhea-type irritable bowel syndrome diseases is discovered for the first time, early diagnosis of diarrhea-type irritable bowel syndrome is realized, and the kit has the advantages of high specificity, high sensitivity, simplicity in collection and treatment of detection objects, no invasion, low cost and the like; and the discovery of the marker provides reference for diagnosing the microbial diarrhea-type irritable bowel syndrome.

The invention discloses a Crohn's disease (CD) related microbial marker set and application thereof in preparation of a CD detection reagent or detection kit. The CD related microbial marker set comprises 34 human intestinal microorganisms screened specifically, has high accuracy when used for diagnosing CD, and can realize early screening of the CD, save time for patients, achieve early treatmentand improve the treatment effects. The invention also discloses application of the CD related microbial marker set in CD detection. Human excrement is taken as a sample, the operation and transportation are convenient, the accuracy of detection results reaches 95.2%, and the sensitivity reaches 91.4%. The invention also discloses the CD detection kit comprising the CD related microbial marker set. The CD detection kit is convenient to use, can comprehensively detect and monitor intestinal flora difference conditions in a disease state, and is used for early discovery of CD patients.

The invention discloses a microbial flora marker for evaluating the chemotherapy curative effect of pancreatic cancer and an application of the microbial flora marker, belongs to the technical field of medical detection. By obtaining the relative abundance content of the microbial marker and giving a prediction probability through model calculation, the microbial flora marker can be used for assisting in evaluating the chemotherapy curative effect of pancreatic cancer, reducing an improper chemotherapy cycle and buying time for effective treatment of a patient.

The invention discloses application of a microbial marker in cerebral infarction diagnosis and treatment effect evaluation. Specifically, the microbial marker is Vampirovibrio. According to the application of the microbial marker in cerebral infarction diagnosis and treatment effect evaluation, the drug intervention effect of a subject can be judged by detecting the abundance of the Vampirovibrioin a sample of the subject. Meanwhile, the invention also provides the application of the microbial marker in treatment of cerebral infarction.

The invention discloses a myasthenia gravis diagnostic reagent kit taking microorganisms as diagnostic markers and an application. The reagent kit comprises a reagent capable of detecting the microbial markers, and the microorganisms are Prevotella_stercorea or a combination of the Prevotella_stercorea and Sutterella_parvirubra. The myasthenia gravis can be predicted, and a rapid diagnostic reagent for preventing and diagnosing myasthenia gravis is developed.

The invention relates to ankylosing spondylitis intestinal microbial markers, in particular to an ankylosing spondylitis intestinal microbial marker and application thereof. Detecting abundance variation of the microbial marker can be used for determining probability of individuals with ankylosing spondylitis. The microbial marker and a method for early non-invasive diagnosis of ankylosing spondylitis disease states are provided and can be applied to preparation of medicines for ankylosing spondylitis treatment and balancing of intestinal flora micro-environmental steady states according to different intestinal florae of subjects.

The invention relates to an application of intestinal flora in nerve injury detection. The intestinal flora is pseudomonas aeruginosa, veillonella and streptococcus digestive. According to the invention, the horizontal change of the specific flora in nerve injury is firstly discovered, the nerve injury diagnosis can be achieved by detecting the change of the specific flora, and with the application of the microbial marker to diagnose, the operation is simple, the specificity is high, and the sensitivity is strong.

The invention provides application of microbial markers in identifying and / or distinguishing individuals of different nationalities. The microbial markers are of the genus Prevotella.

The invention discloses a microbial marker for bovine endometritis. The microbial marker comprises the following microorganisms with remarkably increased abundance: Bacteriodetes, Elusimicrobia, Verrucomicrobia, Spirochaetae and Lentisphaerae. The microbial marker also comprises the following microorganisms with remarkably increased abundance: Akkermansia, biogas bacillus, CF231 and Oscillosporia.The microbial marker also comprises the following microorganisms with remarkably decreased abundance: Ureaplasma urealyticum, Butyrivibrio, Doria, Sphingomonas sp, Rothia and Streptococcus. The invention discloses an application of the microbial marker for bovine endometritis in preparation of a tool for early screening or prediction of bovine endometritis. The applicant performs 16S rRNA gene sequencing on microbial DNA of a uterine mucus sample, compares structural differences of uterine florae between healthy and sick dairy cows, and finds differences in microbial community composition ofthe uterine florae between the healthy and sick dairy cows. The result provides a theoretical basis for better prevention and treatment of clinical endometritis.

The invention provides a microbial marker related to colorectal cancer and an application of the microbial marker. The microbial marker comprises the following components: a microbial marker 1) Peptostreptococcus stomatis; a microbial marker 2) Porphyromonas asaccharolytica; and a microbial marker 3) is Gemella morbillorum. The abundance of the three kinds of bacteria in colorectal cancer patientsis remarkably increased. The invention also provides an application of the biomarker as a detection target in preparation of a detection reagent or a kit and an application in prediction of colorectal cancer risk. The microbial marker disclosed by the invention has the potential of serving as a colorectal cancer marker, is high in accuracy and good in specificity, and has the effect of non-invasive auxiliary diagnosis of colorectal cancer.

The invention discloses an intestinal metagenomic feature used as a fecal microbiota transplantation curative effect screening marker for type 2 diabetes mellitus patients. The intestinal microbe metagenomic feature is Rinkenellaceae family and Anerotrunk family intestinal flora, and the type 2 diabetes mellitus patient suitable for fecal microbiota transplantation treatment are selected according to the expression levels of the specific intestinal flora markers. Corresponding detection kits are designed and developed according to the intestinal flora biomarkers and different detection technology platforms. The system and the product can be used for precise treatment of type 2 diabetes mellitus based on individualization.

The present invention discloses a microorganism associated with recurrent abortion and an application thereof. The specific microorganism is Anaerococcus hydrogenalis and abundance of the Anaerococcushydrogenalis in patients with unexplained recurrent abortion is significantly increased, suggesting that the Anaerococcus hydrogenalis can be used as a microorganism marker applied in an early diagnosis of the unexplained recurrent abortion.